NR2F6 Modulation for Leukemia Stem Cell Targeting
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapies for myelodysplastic syndrome (MDS) and acute leukemia are ineffective due to their inability to target leukemia stem cells specifically, leading to debilitating treatments and poor patient outcomes, while the role of NR2F6 in hematopoiesis and its potential as a regulator of stem cell self-renewal and differentiation remains poorly understood.
Innovation Solution
Modulating NR2F6 levels using inhibitors or activators, such as antisense nucleic acids, blocking antibodies, or shRNA molecules, to inhibit self-renewal or induce differentiation of stem cells, thereby addressing the underlying pathology of MDS and leukemia by targeting NR2F6 in hematopoietic and leukemia stem cells.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current therapies are used to treat MDS and acute leukemia, then treatment is provided, but the therapies are ineffective and cause debilitating side effects due to inability to target leukemia stem cells specifically
Solution Approach 1:
The patent extracts and targets the specific molecular function of NR2F6 in leukemia stem cells, separating the therapeutic action from non-specific cytotoxic effects. By focusing on NR2F6 modulation, the therapy achieves selective efficacy against CSCs while reducing harm to normal cells.
Solution Approach 2:
The invention applies local quality by targeting a specific molecular pathway (NR2F6) within specific cell types (leukemia stem cells). This localized molecular targeting enables effective treatment of the disease根源 while minimizing widespread toxicity.
2Reliability
If NR2F6 is modulated to inhibit self-renewal and promote differentiation, then stem cell pathology is addressed, but the mechanism and specificity of this modulation were previously unknown
Solution Approach 1:
The patent performs preliminary molecular characterization of NR2F6 in hematopoietic and leukemia stem cells to establish its functional role before developing therapeutic interventions. This preliminary understanding enables specific and reliable therapeutic targeting.
Solution Approach 2:
The invention employs feedback mechanisms through the modulation of NR2F6 expression or activity, where the therapeutic agent monitors and adjusts the self-renewal and differentiation balance in stem cells to achieve desired therapeutic outcomes.
Data Source
AI summary
The application provides methods of modulating NR2F6 in a cell or animal in need thereof by administering an effective amount of a NR2F6 modulator.